Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
More Reading from MarketBeat 3 Stocks Under $5 With Strong Analyst Upside PotentialSubmitted by Chris Markoch. First Published: 2/24/2026. 
Key Points - Grab Holdings is gaining analyst support as revenue growth and its first full year of profitability highlight long-term opportunity in Southeast Asia’s expanding digital economy.
- Vaxart offers speculative biotech upside with its oral vaccine platform targeting influenza, norovirus, and COVID-19, creating a high-risk, high-reward setup.
- ThredUp is positioned to benefit from the fast-growing resale market, with strong institutional ownership and industry forecasts pointing to sustained secondhand demand.
- Special Report: [Sponsorship-Ad-6-Format3]
While many investors are rotating out of speculative penny stocks, others still embrace the risk-reward tradeoff. Stocks that trade for under $5 carry significant risk: many are unprofitable or generate little to no revenue. Most are small-cap companies, a group that has been beaten up in recent years. Even though the Russell 2000 shows signs of recovery, that strength hasn't been broad-based across the small-cap sector. I Called Black Monday. Now I'm Calling March 26!
I predicted the 1987 crash six weeks early. I called the fall of the Berlin Wall. I pinpointed the exact bottom in 2009.
Now I'm staking my reputation on March 26, 2026 - the day I believe Elon will announce the SpaceX IPO.
Bloomberg is calling it "the biggest listing of ALL TIME."
A $1.5 TRILLION valuation... the "wealth-building" moment of the decade.
Today, I'll show you how to get in before the big announcement. Click Here to See How to Secure Your "SpaceX Access Code" That may change in 2026, particularly if the economic outlook continues to improve. In that scenario, money could flow back into speculative names. As with any part of the market, though, quality matters. One way to filter for quality is to look for names with positive analyst sentiment. These three stocks fit that bill. Each lets investors open a potentially sizable position with a modest outlay and still offers meaningful upside over the next five years. Profitability Milestone Meets Long-Term Emerging Market Growth Emerging-market stocks are expected to be beneficiaries in 2026, but that hasn't been the case for Grab Holdings Inc. (NASDAQ: GRAB), which is down about 15% year-to-date. Based in Singapore, Grab operates a "super app" that blends technology, e-commerce and fintech services. A factor in the recent pullback is its proposed merger with Indonesian ride-hailing rival GoTo. The deal is not final and could be materially affected by legislative changes in Indonesia that might constrain earnings potential there. Grab also slightly missed top-line expectations in its Q4 2025 earnings report. Still, revenue rose 19% year-over-year (YOY), and the period marked the company's first full year of profitability. Analysts are forecasting roughly 120% earnings growth over the next 12 months. That helps explain continuing bullish sentiment: the consensus price target of $6.47 implies roughly 54% upside from current levels. High-Risk Biotech With Platform Potential Biotech is a common hunting ground for penny-stock investors because of its high risk-reward profile. One name to watch is Vaxart Inc. (OTCMKTS: VXRT). It's the only company on this list that meets the classic penny-stock definition—trading just over $0.60 per share at the time of writing. Analyst coverage is light: one analyst in the past 12 months rated it a Buy with a $2 target. It's not unusual for analysts to ignore some biotech companies. Vaxart is a clinical-stage firm, meaning all of its candidates remain in clinical trials. The upside is clear: Vaxart is developing oral vaccines, primarily for influenza, norovirus and COVID-19. Besides the convenience and avoidance of needle-related fear, the company says its platform may elicit a broader immune response that could provide wider protection. Institutional ownership is only about 18%, but dollar-volume inflows outnumber outflows by nearly 10:1. Resale Tailwinds Could Turn Today's Losses Into Tomorrow's Gains ThredUp Inc. (NASDAQ: TDUP) is down about 33% in 2026, but over the last 12 months the stock is up more than 66%. Viewed this way, the recent decline appears to be a pullback amid broader investor aversion to unprofitable companies. In ThredUp's case, "unprofitable" may be a temporary label. The company operates an online consignment and thrift marketplace that is gaining traction with Gen Z: in its most recent quarter, revenue rose 12.5% year-over-year. ThredUp cites a GlobalData 2025 market survey forecasting that the U.S. secondhand market's gross merchandise value will grow at a 9% compound annual growth rate through 2029. Institutional investors own roughly 89% of the shares. In dollar terms, buying has outpaced selling about 2:1, and in terms of count, buyers outnumber sellers about 3:1. However, short interest is around 17%, which could increase near-term volatility. The six-analyst consensus price target is $12.50, implying upside of over 190% from current levels.
| 
